Drug intelligence / Profile preview

nivolumab + BMS-986253

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

The combination of nivolumab (a PD-1 immune checkpoint inhibitor) and BMS-986253 (an anti-interleukin 8 [IL-8] monoclonal antibody) is an investigational immunotherapy regimen for advanced cancers. Nivolumab blocks the PD-1 receptor, enhancing T-cell activity against tumors. BMS-986253 binds to free IL-8, preventing its signaling through CXCR1 and CXCR2 receptors, which may reduce recruitment of immunosuppressive myeloid-derived suppressor cells to the tumor microenvironment and improve immune-mediated tumor cell lysis. This combination aims to overcome resistance to checkpoint inhibitors by targeting both adaptive and innate immune escape mechanisms.

Brand names: Opdivo
Other names: HuMax-IL8HuMax-IL-8HuMax-IL 8

Targets

IL8 (C-X-C Motif Chemokine Ligand 8)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on nivolumab + BMS-986253.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nivolumab + BMS-986253.

Explore the full profile